作者: 公豬 時(shí)間: 2025-3-21 23:10 作者: predict 時(shí)間: 2025-3-22 03:03
Pathophysiology of Allergic Airways Disease,nsional diagnostic approach. Furthermore, this chapter sheds light on the implications of these findings for clinical practice and research, advocating for personalized therapeutic strategies and further interdisciplinary studies to propel advancements in the field, ultimately enhancing patient care and outcomes.作者: bacteria 時(shí)間: 2025-3-22 06:47 作者: affinity 時(shí)間: 2025-3-22 10:31
chnology in diagnosis and management.Discovers future direct.The book explores the intersection of nanotechnology and allergic airway diseases. With a focus on diagnosis and management, each chapter delves into specific areas of interest. Beginning with an introduction to the diseases, the book prog作者: 迅速成長(zhǎng) 時(shí)間: 2025-3-22 16:05 作者: ADOPT 時(shí)間: 2025-3-22 17:35 作者: 別名 時(shí)間: 2025-3-22 21:45 作者: 彩色的蠟筆 時(shí)間: 2025-3-23 03:10 作者: violate 時(shí)間: 2025-3-23 08:30 作者: 山羊 時(shí)間: 2025-3-23 11:54 作者: 聯(lián)想記憶 時(shí)間: 2025-3-23 17:30 作者: Emg827 時(shí)間: 2025-3-23 21:10
Carbon Nanotubes (CNTs): A Novel Therapeutic Approach in the Management of Allergic Airway Diseases survival due to decreased bioavailability. Nanoparticle discoveries improved the therapeutic efficacy allowing for extensive functionalization. Carbon nanotubes hold promising effects for bringing revolution worldwide in drug delivery systems. They offer the potential for improved therapeutic effic作者: Spinous-Process 時(shí)間: 2025-3-23 23:01
Liposomes for the Management of Allergic Airway Diseases,lergic bronchopulmonary aspergillosis are a few examples of these disorders. For treating allergic obstructive pulmonary illnesses, liposomes provided several benefits, including improved drug stability, prolonged drug release, targeted drug delivery inside the airways, etc. The application of lipos作者: PON 時(shí)間: 2025-3-24 03:00 作者: 大量 時(shí)間: 2025-3-24 08:23
Solid Lipid Nanoparticles for the Management of Allergic Airway Diseases, special attention for control and prevention. Various conventional drug moieties are available for treatment of allergic airway diseases, but these drug moieties show therapeutic inefficiency due to poor aqueous solubility, low bioavailability, higher adverse effects, lack of drug targeting, and dr作者: fetter 時(shí)間: 2025-3-24 12:22 作者: thrombus 時(shí)間: 2025-3-24 17:05
Nanofibers for the Management of Allergic Airway Disease,o particular allergens. The process of allergy starts with the entry of allergen into the airways, which triggers the immunogenic reaction though several processes and may cause several pathological morbidities including inflammation. Treating allergic responses in airways is the biggest challenge a作者: orthopedist 時(shí)間: 2025-3-24 19:58 作者: fatuity 時(shí)間: 2025-3-25 02:34 作者: spinal-stenosis 時(shí)間: 2025-3-25 06:06 作者: Blood-Clot 時(shí)間: 2025-3-25 09:46
Gaurav Gupta,Riya Thapa,Asif Ahmad Bhat,Sarita Rawat,Karuna Dhaundhiyal,Ishwar Singh Dhramshaktu,Abh作者: 人造 時(shí)間: 2025-3-25 12:04
Mohit Agrawal,Anurag Mishra,Abhishek Dwivedi,Yogendra Singh作者: 值得尊敬 時(shí)間: 2025-3-25 17:07
C. Sarath Chandran,Krishnameera Sajayan,P. K. Anjana,K. K. Swathy,Alan Raj,Amna Mohammed Mohamed AlS作者: Budget 時(shí)間: 2025-3-25 21:26 作者: Anhydrous 時(shí)間: 2025-3-26 03:33
Girish Kumar,Reshu Virmani,Ashwani Sharma,Tarun Virmani,Kamla Pathak作者: armistice 時(shí)間: 2025-3-26 08:20
Nitin Sharma,Akshita Arora,Amit Chaudhary,Anjana Sharma,Namita Aggarwal作者: 一再煩擾 時(shí)間: 2025-3-26 11:39
Parteek Prasher,Mousmee Sharma,Sachin Kumar Singh,Ronan MacLoughlin,Kavita Pabreja,Kamal DuaSelected Papers作者: forbid 時(shí)間: 2025-3-26 12:59
Correction to: Understanding Allergic Airway Diseases: Contemporary Treatment Paradigm,作者: entitle 時(shí)間: 2025-3-26 19:55 作者: fertilizer 時(shí)間: 2025-3-26 22:46
Immunology of Allergic Airway Diseases,ls, is a promising example of the success that may be achieved by adopting a different approach. However, patient access to therapy in chronic illnesses affecting large populations is complicated by major payment hurdles associated with biologic medicines like omalizumab. The present study aims to e作者: vibrant 時(shí)間: 2025-3-27 02:19 作者: 直覺(jué)沒(méi)有 時(shí)間: 2025-3-27 06:26 作者: Customary 時(shí)間: 2025-3-27 12:38 作者: Mri485 時(shí)間: 2025-3-27 13:45 作者: Credence 時(shí)間: 2025-3-27 19:45
Liposomes for the Management of Allergic Airway Diseases,ic airway disorders. By promoting immunological tolerance and immune response modulation, these liposomes can lessen allergic inflammation and symptoms. Antibodies or ligands that precisely target receptors or cells involved in allergic airway inflammation can be attached to the surface of liposomes作者: 沒(méi)血色 時(shí)間: 2025-3-27 22:44
Nanoparticles Solutions for Allergic Airway Disorders: Current Trends and Future Prospects,operties to suit patient needs and specific disease characteristics. In the coming years, sustained research efforts and interdisciplinary collaboration will be crucial in advancing the development of nanoparticles for treating airway diseases. As we venture into this realm of science, our aspiratio作者: INCH 時(shí)間: 2025-3-28 02:38 作者: Fracture 時(shí)間: 2025-3-28 09:13
Role of Dendrimers in Management of Allergic Airway Diseases, asthma management. Rigorous clinical trials are necessary for establishing safety and efficacy, paving the way for personalized asthma treatments. Collaborative efforts among researchers, clinicians, and formulation scientists are crucial for translating dendrimer-based therapies into routine clini作者: 沖擊力 時(shí)間: 2025-3-28 14:12
Quantum Dots for the Management of Allergic Airway Diseases,e cellular level. Many recent examples suggest that a variety of bioactive compounds can be functionalized over quantum dots to specifically target allergic airway diseases and also provide a sustained and controlled release. There are a few known issues pertaining to the biocompatibility of functio作者: 不愛(ài)防注射 時(shí)間: 2025-3-28 16:48 作者: CLEAR 時(shí)間: 2025-3-28 22:25 作者: WAIL 時(shí)間: 2025-3-29 01:26
978-981-97-1955-6The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapor作者: REIGN 時(shí)間: 2025-3-29 06:47 作者: 教義 時(shí)間: 2025-3-29 08:56
http://image.papertrans.cn/u/image/941296.jpg作者: LEVY 時(shí)間: 2025-3-29 13:07
https://doi.org/10.1007/978-981-97-1953-2Immunology; Epidemiology; Pathophysiology; Nanomicelles; Metal oxide nanoparticles; Nanofibers; Liposomes作者: animated 時(shí)間: 2025-3-29 18:39
7樓作者: Infinitesimal 時(shí)間: 2025-3-29 21:28
8樓作者: 煩憂 時(shí)間: 2025-3-30 03:11
8樓作者: probate 時(shí)間: 2025-3-30 05:05
8樓作者: 加劇 時(shí)間: 2025-3-30 09:24
8樓作者: single 時(shí)間: 2025-3-30 15:43
9樓作者: 利用 時(shí)間: 2025-3-30 18:50
9樓作者: incubus 時(shí)間: 2025-3-30 21:47
9樓作者: Arthr- 時(shí)間: 2025-3-31 04:33
9樓作者: 階層 時(shí)間: 2025-3-31 05:18
10樓作者: Osteons 時(shí)間: 2025-3-31 09:45
10樓作者: frozen-shoulder 時(shí)間: 2025-3-31 15:31
10樓作者: MODE 時(shí)間: 2025-3-31 18:00
10樓
